• Regulatory

Boyds bolsters US team with hire of experienced product development professional

Leading global drug development consultancy Boyds has bolstered its US team with the appointment of experienced pharmaceutical product development professional Ami Patel PhD

CEO Update | 1 August 2022

Last week we released our Genomics Nation 2022 report, in partnership with the Medicines Discovery Catapult and Wellcome Sanger Institute, which showcases the strengths and opportunities of this vibrant UK ecosystem of entrepreneurs, spin-outs and scale-ups. Read for more on the innovative UK genomics companies that are vital to the future wealth of our nation and for our response to DHSC consultation on the future strategy for batch testing of medicines in Great Britain.

CEO Update | 27 June 2022

I was delighted to see the announcement from Moderna that it has chosen the UK to base its mRNA Innovation and Technology Centre and an additional mRNA manufacturing centre. Alongside other recent investments from the likes of Fujifilm and ThermoFisher, the UK is now superbly placed to ensure the next generation of therapeutics and vaccines are developed and manufactured for the globe right here within our world-class ecosystem.

CEO Update | 30 May 2022

As we celebrate the Queen’s Platinum Jubilee it was great to see the King and Queen of Sweden visiting AstraZeneca in Cambridge last week. The visit provided the platform for the UK government to sign its first Memorandum of Understanding (MoU) with Sweden regarding life sciences. The MoU promises to lead to "enhancing cooperation between our governments and to galvanise our life sciences ecosystems in working together on our shared strengths and common priorities, covering fields from precision medicine, clinical trials, pandemic preparedness and antimicrobial resistance to sustainability, trade, and investment for the sector."

CN Bio introduces PhysioMimix NASH ‘in-a-box’ reagent kit

First product within new ‘in-a-box’ range, which harnesses next-generation, human-relevant Liver-on-a-Chip technology to improve the accuracy and efficiency of NASH drug discovery

CEO Update | 25 April 2022

It is great to see our ecosystem back out and about in person this Spring – and especially to be joined by 200 colleagues from across the biotech and life sciences sector at our London Regional event last week. The discussion on funding alternatives to IPO for scaling biotechs was both insightful and inspiring and provoked lots more conversations in the vibrant networking that followed. Read on for updates on WuXi healthcare forum, just published BIA quarterly influence report, Valneva approval and more...

EuropaBio published policy recommendations for the healthcare and industrial biotechnology sectors

EuropaBio has published the National Associations Council Summit 2022 Event Report ''Biotechnology: Delivering Europe’s industrial strategy across the sectors''. The report includes key policy recommendations for healthcare and industrial biotechnology sectors at national and the EU level which could serve the policymakers to get a better understanding of the sector’s potential and regulatory challenges in operating on the national and EU level.

NICE reaches important milestone in the UK’s efforts to tackle antimicrobial resistance.

Two new antimicrobial drugs - cefiderocol and ceftazidime–avibactam - are close to becoming the first to be made available as part of the UK’s innovative subscription-style payment model after NICE today (Tuesday, 12 April 2022) published draft guidance estimating their value to the NHS.

CEO Update | 11 April 2022

Last week, we released new data showing that UK biotech companies continue to demonstrate they command the confidence of global venture capital(VC) investors with £453m raised in the first quarter of 2022. The first quarter is the best for UK biotech VC financing ever recorded by BIA and Clarivate and neither the US nor China enjoyed the same year on year growth. The data was covered in this weekend’s Sunday Times with analysis from our Head of Policy and Public Affairs, Dr Martin Turner.

tranScrip accelerates growth and expands service capabilities with key acquisition

tranScrip, the fast-growing contract drug development organisation which supports the development and lifecycle of medicines, has acquired Dublin-based Real Regulatory, a highly respected business specialising in European regulatory affairs, quality systems and compliance for medical products.